Interventional News Issue 66 – June 2017

588

Highlights:

ATTRACT trial results a catalyst for advance in management of deep vein thrombosis
SIRT significantly better tolerated than sorafenib, but does not increase overall survival in hepatocellular carcinoma patients
Matthew Callstrom: IO updates
Andrew Holden: PAD trials
Profile: Bob Abraham

(Visited 230 times, 1 visits today)

LEAVE A REPLY

Please enter your comment!
Please enter your name here